Dana Investment Advisors Inc. Buys Shares of 5,313 Regeneron Pharmaceuticals, Inc. $REGN

Dana Investment Advisors Inc. purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in the 3rd quarter, according to the company in its most recent filing with the SEC. The fund purchased 5,313 shares of the biopharmaceutical company’s stock, valued at approximately $2,987,000.

Several other large investors have also bought and sold shares of the business. Salomon & Ludwin LLC acquired a new stake in Regeneron Pharmaceuticals during the 3rd quarter worth $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $31,000. Traub Capital Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the second quarter worth $38,000. E Fund Management Hong Kong Co. Ltd. lifted its stake in Regeneron Pharmaceuticals by 87.5% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 75 shares of the biopharmaceutical company’s stock valued at $42,000 after buying an additional 35 shares during the period. Finally, Berbice Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 300.0% during the second quarter. Berbice Capital Management LLC now owns 80 shares of the biopharmaceutical company’s stock worth $42,000 after buying an additional 60 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Trading Up 1.6%

REGN opened at $784.28 on Thursday. The stock has a market capitalization of $82.91 billion, a P/E ratio of 18.87, a P/E/G ratio of 2.07 and a beta of 0.40. Regeneron Pharmaceuticals, Inc. has a 12 month low of $476.49 and a 12 month high of $821.11. The firm’s fifty day simple moving average is $770.88 and its 200 day simple moving average is $678.50. The company has a current ratio of 4.13, a quick ratio of 3.39 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Friday, January 30th. The biopharmaceutical company reported $11.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.74 by $0.70. The firm had revenue of $3.88 billion during the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a return on equity of 13.04% and a net margin of 31.41%.The company’s revenue was up 2.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $12.07 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 5th. Shareholders of record on Friday, February 20th will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date is Friday, February 20th. This is a positive change from Regeneron Pharmaceuticals’s previous quarterly dividend of $0.88. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 9.05%.

Key Stories Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: FDA approved Dupixent for allergic fungal rhinosinusitis (AFRS) in patients aged 6+, marking the drug’s ninth U.S. indication and addressing a hard-to-treat sinus disease; approval is supported by Phase 3 data showing symptom reduction and lower need for steroids or repeat surgery, boosting Dupixent’s long-term revenue potential. GlobeNewswire: Dupixent approved for AFRS
• Positive Sentiment: Regeneron and Sanofi announced the same FDA approval in commercial/press coverage highlighting strong Phase 3 data and broader market adoption potential for Dupixent across sino-nasal and type 2 inflammatory diseases. Yahoo: Dupixent AFRS coverage
• Positive Sentiment: The FDA accepted Regeneron’s BLA for garetosmab under Priority Review for fibrodysplasia ossificans progressiva (FOP), accelerating the regulatory timeline for a potential new orphan indication and adding near-term pipeline value if approved. Yahoo: FDA accepts garetosmab BLA
• Positive Sentiment: Analyst and media bullish takes (e.g., The Motley Fool) highlight Regeneron’s product depth, manufacturing capabilities and combined commercial strength with Sanofi as reasons the stock could outperform long-term — supportive commentary that can sustain investor interest after the approval news. Fool: Reasons REGN could outperform
• Neutral Sentiment: Market commentary is flagging short-term price cooling and a valuation reassessment despite recent gains; investors are revisiting multiples and growth assumptions after mixed short-term returns. Yahoo: Valuation assessment
• Neutral Sentiment: Recent MarketBeat coverage notes a modest dividend increase and a range of analyst target revisions — supportive but incremental to valuation — with consensus still in the moderate-buy area. MarketBeat: Analyst notes & dividend
• Negative Sentiment: Regeneron director Huda Zoghbi sold 1,638 shares (~49% reduction of her holding) in a disclosed transaction; while insider sales are common and may be for personal reasons, large disclosed sales can create short-term selling pressure or raise governance questions for some investors. American Banking News: Insider sale

Analyst Ratings Changes

A number of analysts have recently commented on the company. JPMorgan Chase & Co. upped their price target on Regeneron Pharmaceuticals from $850.00 to $950.00 and gave the company an “overweight” rating in a research note on Monday, February 2nd. Truist Financial lowered their target price on shares of Regeneron Pharmaceuticals from $820.00 to $818.00 and set a “buy” rating for the company in a research note on Monday, February 2nd. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $865.00 to $975.00 and gave the stock a “buy” rating in a research report on Monday, February 9th. HSBC began coverage on shares of Regeneron Pharmaceuticals in a report on Monday, November 24th. They issued a “buy” rating and a $255.00 price target for the company. Finally, UBS Group raised their price objective on Regeneron Pharmaceuticals from $595.00 to $660.00 and gave the stock a “neutral” rating in a research note on Friday, November 7th. Two investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $793.81.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Bonnie L. Bassler sold 1,500 shares of the company’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director owned 1,703 shares of the company’s stock, valued at $1,362,400. This represents a 46.83% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Jason Pitofsky sold 2,036 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $778.52, for a total transaction of $1,585,066.72. Following the completion of the sale, the senior vice president owned 4,272 shares in the company, valued at $3,325,837.44. This trade represents a 32.28% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 5,274 shares of company stock worth $4,142,738. 7.02% of the stock is currently owned by insiders.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.